Category Archives: Investment

Healthcare stocks have rough week as TherapeuticsMD, NantHealth fall flat; but Neurocrine, Tocagen shine

TherapeuticsMD Inc.(NYSE: TXMD) led a large contingent of stocks performing faceplants among the healthcare ranks. The clinical-stage biotech company focused on women’s health, plummeted $2.19, or 28%, to $7.70 in… Read more »

Week’s opening stock roundup: gainers include Novocure, Steadymed; but Corvus, NewLink rocked

Here to start your trading week are the major movers from last week and where they stand this morning: Novocure (Nasdaq: NVCR) led advancing issues, soaring $3.25, or 40% over the… Read more »

Canadian biopharma Zymeworks files for $75 million IPO; name may sound funky but gameplan dead serious

Biopharmaceutical company Zymeworks Inc. (Vancouver BC) on Monday (April 3, 2107) said it has filed with the US Securities and Exchange Commission for an initial public offering. The company, which… Read more »

Week’s opening stock roundup: Impax, Omeros shine; Foamix down, but not out

1) Impax Laboratories Inc. (Nasdaq:IPXL) led advancing issues, rocketing $3.40, or 37% over the week, to $12.65. The upward move came after the company reported it has hired Allergan PLC’s… Read more »

Week’s opening stock salvo: Cellect, Impax, Cancer Genetics celebrate; Foamix, not so much

After the resounding thud heard round-the-world Friday upon the failure of Trumpcare, healthcare stocks were back in vogue with investors Monday (March 27, 2017). Here are the top stars and… Read more »

Stock markets closed Friday prior to collapse of Trumpcare; health sector’s biggest winners & losers as of March 24, 2017

Republican bickering has led to the biggest rout yet for President Trump’s early administration. As I expected, the GOP plan to gut the Affordable Care Act collapsed Friday (March 24,… Read more »

PTC Therapeutics catches falling knife with Emflaza buy; or did it?

Every now and again I’ll read about what seems on its face a boneheaded business deal between two Pharma companies and try to blow the lid off some super-stealthy, strategic,… Read more »

Week’s opening stock salvo: Esperion, Nektar, CytomX soar; Aevi Genomic thrashed

Esperion Therapeutics Inc. (Nasdaq: ESPR) stock recently recovered big time from last Amgen-induced beat down to touch an 18-month high after the company outlined its path to FDA approval for its… Read more »

After 15 years, unheralded French biotech eyeing big payday on cancer breakthrough; “buy” signal–solid

Hidden from view just across the French border from Geneva is a little-known (at least here in the US) biotech eyeing long-awaited FDA approval for a nuclear medicine targeting the… Read more »

Health sector’s biggest winners & losers as of March 17, 2017

Seres Therapeutics Inc. (Nasdaq: MCRB) led advancing issues, soaring $2.71, or 29% for the week, to $12.04. The small microbiome-therapeutics platform company released its fourth-quarter results earlier Thursday (March 16,… Read more »